Skip to main content

Market Overview

Benzinga's Top Upgrades, Downgrades For December 29, 2020

Share:

 

Upgrades

  • For Continental Resources Inc (NYSE:CLR), KeyBanc upgraded the previous rating of Sector Weight to Overweight. Continental Resources earned $0.16 in the third quarter, compared to $0.54 in the year-ago quarter. The current stock performance of Continental Resources shows a 52-week-high of $36.20 and a 52-week-low of $6.90. Moreover, at the end of the last trading period, the closing price was at $16.26.

 

Downgrades

  • For Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT), Raymond James downgraded the previous rating of Outperform to Market Perform. For the third quarter, Arcturus Therapeutics had an EPS of $0.92, compared to year-ago quarter EPS of $0.56. At the moment, the stock has a 52-week-high of $129.71 and a 52-week-low of $8.51. Arcturus Therapeutics closed at $92.42 at the end of the last trading period.
  • According to HC Wainwright & Co., the prior rating for Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) was changed from Buy to Neutral. In the third quarter, Arcturus Therapeutics showed an EPS of $0.92, compared to $0.56 from the year-ago quarter. The current stock performance of Arcturus Therapeutics shows a 52-week-high of $129.71 and a 52-week-low of $8.51. Moreover, at the end of the last trading period, the closing price was at $92.42.
  • For Aprea Therapeutics Inc (NASDAQ:APRE), RBC Capital downgraded the previous rating of Outperform to Sector Perform. For the third quarter, Aprea Therapeutics had an EPS of $0.58, compared to year-ago quarter EPS of $5.29. At the moment, the stock has a 52-week-high of $53.11 and a 52-week-low of $5.35. Aprea Therapeutics closed at $5.50 at the end of the last trading period.
  • Baird downgraded the previous rating for Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) from Outperform to Neutral. For the third quarter, Arcturus Therapeutics had an EPS of $0.92, compared to year-ago quarter EPS of $0.56. At the moment, the stock has a 52-week-high of $129.71 and a 52-week-low of $8.51. Arcturus Therapeutics closed at $92.42 at the end of the last trading period.

 

Initiations

  • Daiwa Capital initiated coverage on Splunk Inc (NASDAQ:SPLK) with a Neutral rating. In the third quarter, Splunk showed an EPS of $0.07, compared to $0.58 from the year-ago quarter. The stock has a 52-week-high of $225.89 and a 52-week-low of $93.92. At the end of the last trading period, Splunk closed at $175.55.
  • Morgan Stanley initiated coverage on Sigilon Therapeutics Inc (NASDAQ:SGTX) with a Equal-Weight rating. The price target for Sigilon Therapeutics is set to $45.00. At the moment, the stock has a 52-week-high of $54.32 and a 52-week-low of $22.00. Sigilon Therapeutics closed at $39.80 at the end of the last trading period.
  • With a Equal-Weight rating, Morgan Stanley initiated coverage on Seer Inc (NASDAQ:SEER). The price target seems to have been set at $65.00 for Seer. At the moment, the stock has a 52-week-high of $86.13 and a 52-week-low of $44.00. Seer closed at $64.40 at the end of the last trading period.
  • SVB Leerink initiated coverage on Silverback Therapeutics Inc (NASDAQ:SBTX) with an Outperform rating. At the moment, the stock has a 52-week-high of $36.70 and a 52-week-low of $24.22. Silverback Therapeutics closed at $36.50 at the end of the last trading period.
  • With a Buy rating, Stifel initiated coverage on Silverback Therapeutics Inc (NASDAQ:SBTX). The price target seems to have been set at $58.00 for Silverback Therapeutics. At the moment, the stock has a 52-week-high of $36.70 and a 52-week-low of $24.22. Silverback Therapeutics closed at $36.50 at the end of the last trading period.
  • Evercore ISI Group initiated coverage on BeyondSpring Inc (NASDAQ:BYSI) with an Outperform rating. The price target for BeyondSpring is set to $30.00. In the third quarter, BeyondSpring showed an EPS of $0.48, compared to $0.37 from the year-ago quarter. The current stock performance of BeyondSpring shows a 52-week-high of $21.50 and a 52-week-low of $9.38. Moreover, at the end of the last trading period, the closing price was at $10.96.
  • Jefferies initiated coverage on Sigilon Therapeutics Inc (NASDAQ:SGTX) with a Buy rating. The price target for Sigilon Therapeutics is set to $60.00. The current stock performance of Sigilon Therapeutics shows a 52-week-high of $54.32 and a 52-week-low of $22.00. Moreover, at the end of the last trading period, the closing price was at $39.80.
  • With an Overweight rating, JP Morgan initiated coverage on Seer Inc (NASDAQ:SEER). The price target seems to have been set at $75.00 for Seer. The stock has a 52-week-high of $86.13 and a 52-week-low of $44.00. At the end of the last trading period, Seer closed at $64.40.
  • For Seer Inc (NASDAQ:SEER), Cowen & Co. initiated coverage, by setting the current rating at Outperform. At the moment, the stock has a 52-week-high of $86.13 and a 52-week-low of $44.00. Seer closed at $64.40 at the end of the last trading period.
  • For Caesarstone Ltd (NASDAQ:CSTE), Benchmark initiated coverage, by setting the current rating at Buy. In the third quarter, Caesarstone showed an EPS of $0.41, compared to $0.29 from the year-ago quarter. At the moment, the stock has a 52-week-high of $15.86 and a 52-week-low of $7.65. Caesarstone closed at $10.80 at the end of the last trading period.
  • Benchmark initiated coverage on Porch Group Inc (NASDAQ:PRCH) with a Buy rating. The price target for Porch Group is set to $24.00. At the moment, the stock has a 52-week-high of $17.31 and a 52-week-low of $14.30. Porch Group closed at $14.71 at the end of the last trading period.
  • HC Wainwright & Co. initiated coverage on Tenax Therapeutics Inc (NASDAQ:TENX) with a Buy rating. The price target for Tenax Therapeutics is set to $5.00. In the third quarter, Tenax Therapeutics showed an EPS of $0.18, compared to $0.33 from the year-ago quarter. The stock has a 52-week-high of $2.68 and a 52-week-low of $0.25. At the end of the last trading period, Tenax Therapeutics closed at $1.07.
  • With a Buy rating, HC Wainwright & Co. initiated coverage on Silverback Therapeutics Inc (NASDAQ:SBTX). The price target seems to have been set at $44.00 for Silverback Therapeutics. The stock has a 52-week-high of $36.70 and a 52-week-low of $24.22. At the end of the last trading period, Silverback Therapeutics closed at $36.50.
 

Related Articles (ARCT + APRE)

View Comments and Join the Discussion!

Posted-In: BZI-RatingsUpgrades Downgrades Initiation Intraday Update Analyst Ratings

Latest Ratings

StockFirmActionPT
ATNXSVB LeerinkDowngrades5.0
XENESVB LeerinkMaintains28.0
DRNAChardan CapitalMaintains34.0
AIPiper SandlerMaintains141.0
QUREChardan CapitalMaintains100.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com